Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

ABSTRACT:

Background

Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.

Results

Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.

Conclusions

In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.

SUBMITTER: Simpson-Yap S 

PROVIDER: S-EPMC9310378 | biostudies-literature |

REPOSITORIES: biostudies-literature